We claim:

- 1. A method for decreasing the appetite of a mammal comprising enterally administering to said mammal an amount of long-chain n-3 PUFA effective to decrease the appetite of said mammal.
- 5 2. The method according to claim 1 wherein said long-chain n-3 PUFA comprises DHA.
 - 3. The method of claim 2 wherein said long-chain n-3 PUFA is administered independent of AA.
 - 4. The method according to claim 1 wherein said long-chain n-3 PUFA is administered during a growth phase prior to or in conjunction with an appetite-impacting stimulus.
- The method according to claim 1 wherein said long-chain n-3 PUFA is administered to an infant in a daily amount of about 8 to about 396 mg/kg body weight.
 - 6. The method according to claim 1 wherein said long-chain n-3 PUFA is administered to a child or an adult in a daily amount of about 84 to about 15,832 mg.
 - 7. A method for modulating the appetite of a mammal comprising enterally administering to said mammal an amount of long-chain n-3 PUFA and an amount of long-chain n-6 PUFA in relative amounts effective to modulate the appetite of said mammal.
 - 8. The method according to claim 7 wherein said long-chain n-3 PUFA comprises DHA and said long-chain n-6 PUFA comprises AA.
 - 9. The method according to claim 7 wherein said long-chain n-3 PUFA is administered during a growth phase prior to or in conjunction with an appetite-impacting stimulus.
 - 10. The method according to claim 7 wherein said long-chain n-3 PUFA is administered to an infant in a daily amount of about 8 to about 396 mg/kg body weight.
 - 11. The method according to claim 7 wherein said long-chain n-3 PUFA is administered to a child or an adult in a daily amount of about 84 to about 15,832 mg.
- 25 12. A method for antagonizing the CB₁ receptor in the brain of a mammal comprising enterally administering to said mammal an amount of long-chain n-3 PUFA effective to antagonize the CB₁ receptor activity in the brain of said mammal.
 - 13. The method according to claim 12 wherein said long-chain n-3 PUFA comprises DHA.
 - 14. The method of claim 12 wherein said long-chain n-3 PUFA is administered
- 30 independent of AA.

20

- 15. The method according to claim 12 wherein said long-chain n-3 PUFA is administered during a growth phase prior to or in conjunction with an appetite-impacting stimulus.
- 16. The method according to claim 12 wherein said long-chain n-3 PUFA is administered to an infant in a daily amount of about 8 to about 396 mg/kg body weight.
- 5 17. The method according to claim 12 wherein said long-chain n-3 PUFA is administered to a child or an adult in a daily amount of about 84 to about 15,832 mg.
 - 18. A method for decreasing the incidence of obesity or overweight status in a population of mammals comprising enterally administering to at least some members of said population an amount of long-chain n-3 PUFA effective to modulate negatively the appetite of said
- 10 mammal.
 - 19. The method according to claim 18 wherein said long-chain n-3 PUFA comprises DHA.
 - 20. The method of claim 18 wherein said long-chain n-3 PUFA is administered independent of AA.
 - 21. The method according to claim 18 wherein said long-chain n-3 PUFA is administered during a growth phase prior to or in conjunction with an appetite-impacting stimulus.
 - 22. The method according to claim 18 wherein said long-chain n-3 PUFA is administered to an infant in a daily amount of about 8 to about 396 mg/kg body weight.
 - 23. The method according to claim 18 wherein said long-chain n-3 PUFA is administered to a child or an adult in a daily amount of about 84 to about 15,832 mg.

15